Lemborexant(Dayvigo)

Since its approval by the U.S. FDA in December 2019, lemborexant, a prescription drug targeting OX1R and OX2R, has been approved in dozens of countries and regions, offering a new option for insomnia patients worldwide. However, it must be used strictly under medical supervision.

Target of Action

OX1R and OX2R

Dosage and Administration

Route and frequency of administration for lemborexant: Oral, once daily.

The dosage of lemborexant should be adjusted based on the patient's actual condition; specific adjustments require consultation with a physician and adherence to medical advice.

Recommended reading: Dosage and Administration of Lemborexant

Side Effects

Common side effects: Somnolence, etc.

Serious side effects: Central nervous system depression and daytime impairment, sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms, etc.

Use in Special Populations

Pregnancy: There are currently no data regarding the use of DAYVIGO in pregnant women.

Lactation: There are currently no data on the effects of lemborexant on breastfed infants or on milk production.

Daily Precautions

1. There is a risk of complex sleep behaviors, including sleepwalking, sleep driving, preparing and eating food, making phone calls, or engaging in sexual activity while not fully awake. Advise patients to immediately discontinue lemborexant and contact their clinician if they experience complex sleep behaviors.

2. Advise patients to be alert and immediately report worsening depression or suicidal thoughts.

3. Inform patients of the abuse potential of this drug. Advise patients not to increase the dose unless instructed by their clinician; if insomnia worsens or does not improve, they should inform their clinician.